These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 16919377)

  • 1. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hallucinations and psychosis in Parkinson's disease.
    Eng ML; Welty TE
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
    Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
    Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressants and psychosis in Parkinson disease: a case series.
    Voon V; Fox S; Butler TR; Lang AE
    Int J Geriatr Psychiatry; 2007 Jun; 22(6):601-4. PubMed ID: 17450623
    [No Abstract]   [Full Text] [Related]  

  • 6. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
    Oechsner M; Korchounov A
    Hum Psychopharmacol; 2005 Apr; 20(3):203-5. PubMed ID: 15799011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological treatment of delusional depression].
    Amore M; Giordani L; Giorgetti G; Zazzeri N
    Minerva Psichiatr; 1996 Mar; 37(1):29-33. PubMed ID: 8804200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emergency treatment of depression complicated by psychosis or agitation.
    Glick RL; Ghaemi SN
    J Clin Psychiatry; 2000; 61 Suppl 14():43-8. PubMed ID: 11154016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
    Merims D; Balas M; Peretz C; Shabtai H; Giladi N
    Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates].
    Kashihara K; Ohno M; Katsu Y
    Rinsho Shinkeigaku; 2005 Jan; 45(1):1-5. PubMed ID: 15714992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosis in Parkinson's disease: case studies.
    Salter BC; Anderson KE; Weiner WJ
    Neurol Clin; 2006 May; 24(2):363-9. PubMed ID: 16684637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to manage depression and psychosis in Alzheimer's disease.
    Tueth MJ
    Geriatrics; 1995 Jan; 50(1):43-6, 49. PubMed ID: 7821828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 15. The treatment of psychotic depression.
    Coryell W
    J Clin Psychiatry; 1998; 59 Suppl 1():22-7; discussion 28-9. PubMed ID: 9448666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use.
    Wolfersdorf M; Barg T; König F; Leibfarth M; Grünewald I
    Pharmacopsychiatry; 1995 Mar; 28(2):56-60. PubMed ID: 7624387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson's disease.
    Masopust J; Urban A; Valis M; Malý R; Tůma I; Hosák L
    Neuro Endocrinol Lett; 2009 Mar; 30(1):19-21. PubMed ID: 19300384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric syndromes in Parkinson's disease.
    Starkstein SE; Brockman S; Hayhow BD
    Curr Opin Psychiatry; 2012 Nov; 25(6):468-72. PubMed ID: 22992542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of behavioural symptoms and dementia in Parkinson's disease.
    Hanagasi HA; Emre M
    Fundam Clin Pharmacol; 2005 Apr; 19(2):133-46. PubMed ID: 15810893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
    da Silva TM; Munhoz RP; Alvarez C; Naliwaiko K; Kiss A; Andreatini R; Ferraz AC
    J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.